Bioassayable growth hormone activity in blood from healthy individuals and acromegalic patients

1986 ◽  
Vol 111 (1) ◽  
pp. 3-9
Author(s):  
Karl-Göran Thorngren ◽  
Bengt Hallengren
Keyword(s):  
Growth Hormone ◽  
Bone Growth ◽  
Normal Subjects ◽  
Healthy Individuals ◽  
Hormone Activity ◽  
Longitudinal Bone Growth ◽  
Biological Growth ◽  
Hypophysectomized Rats ◽  
Growth Activity

Abstract. Biological growth activity (bioassayable GH) was determined in blood from healthy individuals and from patients with acromegaly using the rate of longitudinal bone growth in hypophysectomized rats with tetracycline as intravital marker. Also radioimmunoassayable GH and somatomedin A activity were determined. In pooled plasma or serum from normal subjects no bioassayable growth activity was demonstrated. In the clinically active acromegalic patients as a group as well as in one individual patient there was a significant (P <0.05) bioassayable growth activity in serum as compared to serum from normal subjects. The bioassay determination of GH in plasma/serum from normal subjects and acromegalic patients was hampered by the toxicity and the problems connected with the administration of large volumes.

BIOASSAY OF GROWTH HORMONE AND PROLACTIN PREPARATIONS BY DETERMINATION OF LONGITUDINAL BONE GROWTH WITH TETRACYCLINE

1974 ◽  
Vol 76 (1) ◽  
pp. 35-52 ◽  
Author(s):  
K.-G. Thorngren ◽  
L. I. Hansson
Keyword(s):  
Growth Hormone ◽  
Present Method ◽  
Bone Growth ◽  
Biological Effects ◽  
Human Growth ◽  
Lower Growth ◽  
Longitudinal Bone Growth ◽  
Hypophysectomized Rats ◽  
Growth Promoting

ABSTRACT The growth stimulating effect of different growth hormone and prolactin preparations on the longitudinal bone growth in thyroxine-treated hypophysectomized rats was determined by the tetracycline method. The effect of the hormone preparations was compared with that of the 1st International Standard for growth hormone. The potency calculation showed that the tested human growth hormone preparations have a higher potency than the bovine, ovine and porcine growth hormone preparations. Also potency differences were found between hormones from the same species but prepared by different methods. The prolactin preparations have a considerably lower growth promoting activity than the growth hormone preparations. The bioassay method used in the present investigation has a favourable mean precision (λ = 0.172) and sensitivity compared with the earlier bioassay methods. The present method increases the possibility of determining the biological effects of various growth promoting substances.

BIOASSAY OF GROWTH HORMONE

1974 ◽  
Vol 75 (4) ◽  
pp. 653-668 ◽  
Author(s):  
K.-G. Thorngren ◽  
L. I. Hansson
Keyword(s):  
Growth Hormone ◽  
Bone Growth ◽  
Control Period ◽  
Growth Parameter ◽  
The Body ◽  
Sprague Dawley ◽  
Longitudinal Bone Growth ◽  
Sprague Dawley Rats ◽  
Hypophysectomized Rats ◽  
Operative Control

ABSTRACT The longitudinal bone growth of proximal tibia determined by tetracycline in hypophysectomized rats was used for the bioassay of growth hormone. Female Sprague-Dawley rats were hypophysectomized at 60 days of age and after a post-operative control period of 15 days growth hormone (NIH-GH-B16) was given daily for 5 or 10 days followed by a 10 day period after its withdrawal. A linear log dose-response relation was found for the two administration models with high precision. In the present investigation the longitudinal bone growth was more favourable as a growth parameter for the bioassay of growth hormone than the body weight and the width of the proximal tibial growth plate.

Circumstantial evidence for a role of the secretory pattern of growth hormone in control of body growth

1982 ◽  
Vol 99 (1) ◽  
pp. 24-30 ◽  
Author(s):  
John-Olov Jansson ◽  
Kerstin Albertsson-Wikland ◽  
Staffan Edén ◽  
Karl-Göran Thorngren ◽  
Olle Isaksson
Keyword(s):  
Growth Hormone ◽  
Body Weight ◽  
Replacement Therapy ◽  
Bone Growth ◽  
Injection Period ◽  
Longitudinal Bone Growth ◽  
Long Period ◽  
Hypophysectomized Rats ◽  
Secretory Pattern

Abstract. The effect of frequency of growth hormone (GH) administration on longitudinal bone growth and body weight was studied in hypophysectomized rats which were given replacement therapy with corticosteroids, thyroxine and GH with start of therapy on the day of surgery. Longitudinal bone growth, as determined by the tetracycline method, was measured during the last 5 days of the 9 day long period with replacement therapy. The daily replacement dose of GH (bGH-17:NIH) was 200 μg and was given on 1, 2, 4 or 8 occasions. Longitudinal bone growth was enhanced in the groups of animals receiving the hormone on two or more occasions per day. The most pronounced response was seen with an administration frequency of four times per day. Changes in body weight during the injection period showed similar changes. The results of the present study show that the administration frequency of growth hormone is important for the growth rate in hypophysectomized rats which have been given replacement therapy. The findings suggest that the secretory pattern of GH is an important factor for optimum growth.

EFFECT OF ADMINISTRATION FREQUENCY OF GROWTH HORMONE ON LONGITUDINAL BONE GROWTH IN THE HYPOPHYSECTOMIZED RAT

1977 ◽  
Vol 84 (3) ◽  
pp. 497-511 ◽  
Author(s):  
K.-G. Thorngren ◽  
L. I. Hansson
Keyword(s):  
Growth Hormone ◽  
Total Dose ◽  
Bone Growth ◽  
Growth Stimulation ◽  
Total Daily Dose ◽  
Daily Growth ◽  
Longitudinal Bone Growth ◽  
Hormone Injection ◽  
Injection Frequency ◽  
Hypophysectomized Rats

ABSTRACT The effect of the administration frequency of growth hormone on longitudinal bone growth was investigated with tetracycline as intravital marker of the bone growth of the proximal tibia in hypophysectomized rats. The total dose of growth hormone (NIH-GH-B16) and the administration period were the same in all compared experiments. It was possible to achieve an optimum growth response for a certain total dose of growth hormone by increasing the injection frequency. The period of hormone administration was 10 or 5 days followed by a 10 days withdrawal period. When the growth hormone was administered alone or in association with L-thyroxine for 10 days, the optimum injection frequency for growth hormone was found to be 1 inj./day in hypophysectomized rats and 2 inj./day in thyroxine-treated hypophysectomized rats. When the administration period was 5 days for growth hormone given in association with L-thyroxine, the growth stimulation induced by one daily growth hormone injection was the same as that induced by two or four daily injections of the same total dose. An increase in the administration frequency for a total daily dose of thyroxine from 1 to 2 inj./day did not increase the longitudinal bone growth either when thyroxine was given alone or in association with growth hormone.

Effect of frequency of growth hormone administration on longitudinal bone growth and body weight in hypophysectomized rats

1982 ◽  
Vol 114 (2) ◽  
pp. 261-265 ◽  
Author(s):  
JOHN-OLOV JANSSON ◽  
KERSTIN ALBERTSSON-WIKLAND ◽  
STAFFAN EDÉN ◽  
KARL-GÖRAN THORNGREN ◽  
OLLE ISAKSSON
Keyword(s):  
Growth Hormone ◽  
Body Weight ◽  
Bone Growth ◽  
Longitudinal Bone Growth ◽  
Growth Hormone Administration ◽  
Hormone Administration ◽  
Hypophysectomized Rats

STIMULATION OF LONGITUDINAL BONE GROWTH BY HYPOPHYSEAL HORMONES IN THE HYPOPHYSECTOMIZED RAT

1977 ◽  
Vol 84 (3) ◽  
pp. 485-496 ◽  
Author(s):  
K.-G. Thorngren ◽  
L. I. Hansson
Keyword(s):  
Growth Hormone ◽  
Bone Growth ◽  
Growth Stimulation ◽  
Pituitary Hormones ◽  
Pituitary Hormone ◽  
Longitudinal Bone Growth ◽  
Thyrotrophic Hormone ◽  
Hypophysectomized Rats ◽  
Higher Doses ◽  
Effective Growth

ABSTRACT The stimulating effect of different pituitary hormones on longitudinal bone growth was determined with tetracycline as intravital marker in hypophysectomized rats. Growth hormone was found to be the most effective growth stimulating pituitary hormone. At considerably higher doses, thyrotrophic hormone (TSH) and prolactin also showed growth stimulating activity. TSH exerts its effect via the production of thyroxine, whereas the growth stimulation by prolactin seems to be a direct effect of this hormone, similar to the effect of growth hormone. The LH, FSH, ACTH, MSH, vasopressin and oxytocin preparations did not stimulate longitudinal bone growth.

GROWTH HORMONE AND RADIO-SULFATE INCORPORATION IN COSTAL CARTILAGE

1961 ◽  
Vol 37 (2) ◽  
pp. 176-182 ◽  
Author(s):  
Elliott J. Collins ◽  
Vernon F. Baker
Keyword(s):  
Growth Hormone ◽  
Costal Cartilage ◽  
Time Response ◽  
Hormone Activity ◽  
Reliable Estimation ◽  
Hypophysectomized Rats ◽  
Related Response ◽  
Sulfate Incorporation

ABSTRACT The characteristics and nature of the effect of growth hormone on the incorporation of radio-sulfate into the costal cartilage of hypophysectomized rats has been studied. The time-response studies indicate that a reliable estimation of growth hormone activity can be ascertained within a 24 hour period, and a reproducible dose-related response can be obtained at dosage levels ranging from 12-48 μg. Growth hormone stimulates the synthesis of organic sulfates and accumulation of inorganic sulfates within 48 hours.

BIOASSAY OF GROWTH HORMONE

1974 ◽  
Vol 75 (4) ◽  
pp. 669-682 ◽  
Author(s):  
K.-G. Thorngren ◽  
L. I. Hansson
Keyword(s):  
Growth Hormone ◽  
Bone Growth ◽  
Control Period ◽  
Growth Stimulation ◽  
Sprague Dawley ◽  
Hormone Administration ◽  
Sprague Dawley Rats ◽  
Hypophysectomized Rats ◽  
Operative Control ◽  
Sensitivity Specificity

ABSTRACT The growth stimulating effect of growth hormone was determined with tetracycline as intravital marker of the longitudinal bone growth of proximal tibia in female Sprague-Dawley rats hypophysectomized at 60 days of age. After a post-operative control period of 15 days growth hormone (NIH-GH-B16) was given daily for 5 or 10 days followed by a 10 day period after its withdrawal. L-thyroxine was given in association with the growth hormone administration to potentiate the growth stimulation. A linear log dose-response relation was found for the two administration models with a high precision. The thyroxine-treatment increased the sensitivity of the bioassay. An administration period of 5 days was found sufficient for the bioassay of growth hormone in thyroxine-treated hypophysectomized rats. Compared with the earlier bioassay methods for growth hormone, the present bioassay is more favourable when all the factors, such as precision, sensitivity, specificity, and administration period are considered.

Roentgen Stereophotogrammetry for Determination of Daily Longitudinal Bone Growth in the Rabbit

1978 ◽  
Vol 19 (1A) ◽  
pp. 97-105 ◽  
Author(s):  
A. S. Aronson ◽  
L. I. Hansson ◽  
G. Selvik
Keyword(s):  
Bone Growth ◽  
Longitudinal Bone Growth

IMMUNOREACTIVE GROWTH HORMONE IN HUMAN URINE

1972 ◽  
Vol 71 (4) ◽  
pp. 665-676 ◽  
Author(s):  
Kristian F. Hanssen
Keyword(s):  
Molecular Weight ◽  
Growth Hormone ◽  
Linear Relationship ◽  
Human Urine ◽  
Gel Filtration ◽  
Human Growth ◽  
Normal Subjects ◽  
Normal Human ◽  
Radio Immunoassay

ABSTRACT By using a double antibody radio-immunoassay (pre-precipitation technique) for the determination of immunoreactive human growth hormone (IRHGH) in normal human urine concentrated by dialysis and lyophilization, a factor was revealed that displaces 125I-HGH from HGH antibodies. This displacement was neither due to salts nor to glucose; it is suggested that it is due to IRHGH in the urine. A linear relationship between dilution of urine and the measured IRHGH concentration was obtained. Recovery of exogenous HGH was between 70–105%. The recovery of IRHGH from different volumes of urine following dialysis and lyophilization was between 97–110%. Plasma IRHGH and urinary IRHGH was measured simultaneously after HGH injection in a normal subject. A correlation was shown between plasma IRHGH and urinary IRHGH. In 9 normal subjects, the urinary IRHGH ranged from 28–53 ng/24 h. The excretion of urinary IRHGH was increased in acromegaly and was diminished in some, but not in all patients with adult hypopituitarism. The urinary IRHGH was further studied by gel filtration. It was recovered in one peak corresponding to a molecular weight of approximately 20 000 – 30 000. However, in the present work it was not clarified whether the urinary IRHGH represents pituitary HGH excreted in the urine or a metabolite of high molecular weight with retained immunological properties.

Sign in / Sign up

Export Citation Format

Share Document